Cytotoxicity and cell cycle changes in prostate cancer cells with differing PSMA expression and p53 status after treatment with PSMA-targeting radioligand [212Pb]Pb-AB001

Vilde Yuli Stenberg, Rugile Liukaityte, Sandra Kvarsvik Kristiansen, Rina Wangen-Riise, Andrius Kleinauskas, Victoria Dunne, Asta Juzeniene · 2025

Read Cytotoxicity and cell cycle changes in prostate cancer cells with differing PSMA expression and p53 status after treatment with PSMA-targeting radioligand [212Pb]Pb-AB001 by Vilde Yuli Stenberg, Rugile Liukaityte, Sandra Kvarsvik Kristiansen, Rina Wangen-Riise, Andrius Kleinauskas, Victoria Dunne, Asta Juzeniene (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12775525.txt.

Description

Vilde Stenberg and co-authors test a targeted radiation drug on prostate cancer cells in the lab. Their 2025 paper uses two cell lines that differ in two traits. One trait is how much of a prostate marker sits on the cell surface. The other is whether a key guard gene still works. The drug seeks the marker and gives off alpha radiation at close range.

The drug slowed growth and killed cells in both lines as dose rose. At strong doses, cells stalled before division and some showed signs of failed division. Cells grown as small balls died more readily than flat layers. Total drug bound to cells, not the guard gene, best foretold harm.

Catalog record

CREATORVilde Yuli Stenberg, Rugile Liukaityte, Sandra Kvarsvik Kristiansen, Rina Wangen-Riise, Andrius Kleinauskas, Victoria Dunne, Asta Juzeniene
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12775525

Browse the full library · About the Tower of Babel